Treats transfusional iron overload. Sold as Ferriprox. Every FDA application for this active ingredient: 3 branded and 3 generic.
As of Nov 14, 2026, FDA lists 6 applications for Deferiprone (sold as Ferriprox), first approved Oct 14, 2011, with 5 new uses approved and 0 published complete response letters.
| Ferriprox (2 Times A Day) | Part D | $36.4M | +18% | 195 |
| Deferiprone (3 Times A Day) | Part D | $17.2M | +82% | 290 |
| Deferiprone | Part D | $8.0M | +11% | 221 |
| Ferriprox | Part D | $3.0M | -16% | 29 |
| Ferriprox (3 Times A Day) | Part D | $1.8M | -20% | 22 |
| Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in SchizophreniaSchizoaffecitve Disorder, Schizophrenia and Schizoaffective Disorder · Amit Lotan | Phase 2 | Recruiting | Aug 12, 2026 |
| Early Screening and Treatment of Heart Complication in Sickle Cell DiseaseSickle Cell Disease · Inova Health Care Services | Phase 2 | Recruiting | Jun 17, 2025 |
| The Effectiveness of the Letrozole-induced Endometrial Preparation Protocol in Frozen-thawed Embryo Transfer (FET)Letrozole, Infertility, Female · International Peace Maternity and Child Health Hospital | Not applicable | Recruiting | Aug 23, 2023 |
| Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction PatientsAcute Myocardial Infarction Type 1 · Rohan Dharmakumar | Phase 2 | Recruiting | Nov 3, 2022 |
| Ferritin and Iron Burden in SAH sIRBSAH, Dementia · Duke University | Phase 1 / Phase 2 | Active, not recruiting | Nov 27, 2018 |
| Oct 14, 2011 | FerriproxNDA 21825 · New molecular entity | Chiesi | 8 | Marketed |
| Sep 9, 2015 | FerriproxNDA 208030 · New dosage form | Chiesi | 5 | Marketed |
| Feb 8, 2019 | DeferiproneANDA 208800 | Taro | 2 | Marketed |
| May 19, 2020 | FerriproxNDA 212269 · New formulation or manufacturer | Chiesi | 3 | Marketed |
| Mar 29, 2021 | DeferiproneANDA 213239 | Hikma | 4 | Marketed |
| Dec 11, 2025 | DeferiproneANDA 220132 | Pharmazone | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Taro
Hikma